EXANE DERIVATIVES - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2022$83,000
-15.3%
60.0%0.00%
Q1 2022$98,0000.0%60.0%0.00%
Q4 2021$98,000
+10.1%
60.0%0.00%
Q3 2021$89,000
-15.2%
60.0%0.00%
Q2 2021$105,000
-23.9%
60.0%0.00%
Q1 2021$138,000
-6.8%
60.0%0.00%
Q4 2020$148,000
-40.6%
60.0%0.00%
Q3 2020$249,000
-13.2%
60.0%0.00%
Q2 2020$287,000
-24.1%
60.0%0.00%
Q1 2020$378,000
-44.2%
60.0%0.00%
Q4 2019$677,000
-99.7%
6
-99.8%
0.00%
-100.0%
Q3 2019$251,267,000
-16.6%
3,7870.0%0.04%
-15.1%
Q2 2019$301,247,000
+44795.2%
3,787
+63016.7%
0.05%
Q1 2019$671,000
+10.9%
60.0%0.00%
Q4 2018$605,000
-31.6%
6
-14.3%
0.00%
Q3 2018$884,000
+50.3%
70.0%0.00%
Q2 2018$588,000
+42.0%
70.0%0.00%
Q1 2018$414,000
-99.3%
7
-99.3%
0.00%
-100.0%
Q4 2017$55,483,000
-81.2%
950
-81.3%
0.01%
-81.8%
Q3 2017$294,608,000
+22034.3%
5,077
+46054.5%
0.06%
Q2 2017$1,331,000110.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders